Spots Global Cancer Trial Database for Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Official Title: A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer

Study ID: NCT03012230

Conditions

Metastatic Malignant Neoplasm in the Bone

Stage IV Breast Cancer AJCC v6 and v7

Triple-Negative Breast Carcinoma

Interventions

Laboratory Biomarker Analysis

Pembrolizumab

Ruxolitinib Phosphate

Study Description

Brief Summary: This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.

Detailed Description: PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) of ruxolitinib phosphate (ruxolitinib) (JAK2 inhibition) in combination with fixed dosing of pembrolizumab (anti PD-1) in patients with advanced/metastatic triple negative breast cancer (TNBC). SECONDARY OBJECTIVES: I. To determine the safety profile of pembrolizumab in combination with ruxolitinib. II. To estimate clinical tumor response in women with TNBC treated with pembrolizumab in combination with ruxolitinib as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. EXPLORATORY/CORRELATIVE OBJECTIVES: I. To assess tumor response with immune related (ir)RECIST and associations with PDJ amplification, PD-L1, PD-L2, JAK2 and phosphorylated (p)STAT3 expression. II. To determine the effect of combination targeted blockade on T- and B- cell immunity to breast cancer tumor antigens. OUTLINE: This is a dose-escalation study of ruxolitinib phosphate. Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and ruxolitinib phosphate orally (PO) twice daily (BID) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study, patients are followed up every 3 or 6 months for up to 2 years.